Yuki Otani

Eli Lilly and Company

Poster(s):

• P1139 - One Subcutaneous Injection of Mirikizumab Is Bioequivalent to 2 Subcutaneous Injections: Results from a Pharmacokinetic Comparability Study in Healthy Participants
  Sunday, October 26, 2025

  3:30 PM - 7:00 PM PDT